Biocartis published a study in JACC Journals on 1,013 Brazilian adults with heart failure and ejection fraction ≤50% who had pathogenic/likely pathogenic variants on germline genotyping considered causal.

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain and blood cancer. Biocartis NV is privately held and headquartered in Mechelen, Belgium.